You are here

Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease.

Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2017 Feb 23;: Authors: Strik AS, van den Brink GR, Ponsioen C, Mathot R, Löwenberg M, D’Haens GR Abstract BACKGROUND: Loss of response to anti-tumour necrosis factor (TNF) therapy in patients with inflammatory bowel disease (IBD) is often caused by anti-drug antibody formation with neutralisation of drug effect. Addition of an immunomodulator has been suggested to reduce immunogenicity, leading to regained response. AIM: To investigate whether addition…

Read More

Editorial: relative efficacy of infliximab and adalimumab in Crohn’s disease in an Australian and New Zealand cohort – authors’ reply.

Editorial: relative efficacy of infliximab and adalimumab in Crohn’s disease in an Australian and New Zealand cohort – authors’ reply. Aliment Pharmacol Ther. 2017 Mar;45(6):856-857 Authors: Radford-Smith GL, Hartnell F, Doecke JD PMID: 28211631 [PubMed – in process] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/28211631?dopt=Abstract

Read More

Dose de-escalation to adalimumab 40 mg every 3 weeks in patients with Crohn’s disease – a nested case-control study.

Related Articles Dose de-escalation to adalimumab 40 mg every 3 weeks in patients with Crohn’s disease – a nested case-control study. Aliment Pharmacol Ther. 2017 Feb 06;: Authors: Van Steenbergen S, Bian S, Vermeire S, Van Assche G, Gils A, Ferrante M Abstract BACKGROUND: Data on dose de-escalation in patients with Crohn’s disease (CD) are limited. AIM: To evaluate outcomes of dose de-escalation from adalimumab (ADM) every other week (EOW) to every three weeks (ETW). METHODS: We selected patients with CD receiving maintenance therapy with ADM 40 mg ETW with…

Read More

Long-term Efficacy and Safety of Adalimumab in Pediatric Patients with Crohn’s Disease.

Long-term Efficacy and Safety of Adalimumab in Pediatric Patients with Crohn’s Disease. Inflamm Bowel Dis. 2017 Jan 26;: Authors: Faubion WA, Dubinsky M, Ruemmele FM, Escher J, Rosh J, Hyams JS, Eichner S, Li Y, Reilly N, Thakkar RB, Robinson AM, Lazar A Abstract BACKGROUND: IMAgINE 1 assessed 52-week efficacy and safety of adalimumab in children with moderate to severe Crohn’s disease. Long-term efficacy and safety of adalimumab for patients who entered the IMAgINE 2 extension are reported. METHODS: Patients who completed IMAgINE 1 could enroll in IMAgINE 2. Endpoints…

Read More

Efficacy of adalimumab in patients with Crohn’s disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study.

Related Articles Efficacy of adalimumab in patients with Crohn’s disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study. Gut. 2017 Jan 24;: Authors: Bouhnik Y, Carbonnel F, Laharie D, Stefanescu C, Hébuterne X, Abitbol V, Nachury M, Brixi H, Bourreille A, Picon L, Bourrier A, Allez M, Peyrin-Biroulet L, Moreau J, Savoye G, Fumery M, Nancey S, Roblin X, Altwegg R, Bouguen G, Bommelaer G, Danese S, Louis E, Zappa M, Mary JY, GETAID CREOLE Study Group Abstract OBJECTIVE: The efficacy of anti-tumour necrosis factors (anti-TNFs)…

Read More

Sex Is Associated with Adalimumab Side Effects and Drug Survival in Patients with Crohn’s Disease.

Sex Is Associated with Adalimumab Side Effects and Drug Survival in Patients with Crohn’s Disease. Inflamm Bowel Dis. 2017 Jan;23(1):75-81 Authors: Lie MR, Kreijne JE, van der Woude CJ Abstract BACKGROUND: Adalimumab (ADA) is an effective treatment for Crohn’s disease (CD). In rheumatology, sex differences concerning the response to ADA therapy have been described. However, such differences have not yet been reported for patients with CD. As such, the aim of this study was to compare ADA treatment outcomes in male and female patients with CD. METHODS: A clinical cohort…

Read More

Infliximab vs. adalimumab in Crohn’s disease: results from 327 patients in an Australian and New Zealand observational cohort study.

Related Articles Infliximab vs. adalimumab in Crohn’s disease: results from 327 patients in an Australian and New Zealand observational cohort study. Aliment Pharmacol Ther. 2016 Dec 19;: Authors: Doecke JD, Hartnell F, Bampton P, Bell S, Mahy G, Grover Z, Lewindon P, Jones LV, Sewell K, Krishnaprasad K, Prosser R, Marr D, Fischer J, R Thomas G, Tehan JV, Ding NS, Cooke SE, Moss K, Sechi A, De Cruz P, Grafton R, Connor SJ, Lawrance IC, Gearry RB, Andrews JM, Radford-Smith GL, Australian and New Zealand Inflammatory Bowel Disease Consortium…

Read More

Adalimumab Maintenance Treatment in Ulcerative Colitis: Outcomes by Prior Anti-TNF Use and Efficacy of Dose Escalation.

Related Articles Adalimumab Maintenance Treatment in Ulcerative Colitis: Outcomes by Prior Anti-TNF Use and Efficacy of Dose Escalation. Dig Dis Sci. 2016 Dec 19; Authors: Taxonera C, Iglesias E, Muñoz F, Calvo M, Barreiro-de Acosta M, Busquets D, Calvet X, Rodríguez A, Pajares R, Gisbert JP, López-Serrano P, Pérez-Calle JL, Ponferrada Á, De la Coba C, Bermejo F, Chaparro M, Olivares D, Alba C, Fernández-Blanco I Abstract BACKGROUND: The impact of prior anti-TNF use on “real-life” outcomes of adalimumab therapy in ulcerative colitis (UC) is not well known. AIM: To…

Read More

Higher Risk of Hospitalization and Serious Infection Among Patients With Ulcerative Colitis Treated with Adalimumab, Compared with Infliximab, in a Nationwide Study.

Higher Risk of Hospitalization and Serious Infection Among Patients With Ulcerative Colitis Treated with Adalimumab, Compared with Infliximab, in a Nationwide Study. Clin Gastroenterol Hepatol. 2016 Nov 29;: Authors: Singh S, Nyboe Andersen N, Andersson M, Loftus EV, Jess T Abstract BACKGROUND & AIMS: We compared the effectiveness and safety of infliximab and adalimumab in biologic-naïve patients with ulcerative colitis (UC), in a nationwide register-based propensity score-matched study of patients in Denmark. METHODS: We collected data from 1719 adults with UC, 15-75 years old, in Denmark who were treated with…

Read More
<< Go Back